General Information of the Drug (ID: M6APDG04302)
Name
O6-Benzylguanine alkylade
Synonyms
KRX-0402; O6-Benzylguanine (BG)
    Click to Show/Hide
Status
Phase 3
TTD Drug ID
D0S0HA
Target Gene(s) and Their Upstream m6A Regulator, Together with the Effect of Target Gene(s) in Drug Response
The target genes involved in drug-target interaction (such as drug-metabolizing enzymes, drug transporters and therapeutic targets) and drug-mediated cell death signaling (including modulating DNA damage and repair capacity, escaping from drug-induced apoptosis, autophagy, cellular metabolic reprogramming, oncogenic bypass signaling, cell microenvironment, cell stemness, etc.) could be regulated by m6A regulator(s) and affected their corresponding drug response. You can browse detailed information on drug-related target gene(s) mediated by m6A regulators.
O-6-methylguanine-DNA-alkyltransferase (MGMT)
Methyltransferase-like 3 (METTL3)
In total 1 mechanisms lead to this potential drug response
Response Summary O-6-methylguanine-DNA-alkyltransferase (MGMT) is a therapeutic target for O6-Benzylguanine alkylade. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of O6-Benzylguanine alkylade through regulating the expression of O-6-methylguanine-DNA-alkyltransferase (MGMT). [1], [2]
References
Ref 1 METTL3 Promotes the Resistance of Glioma to Temozolomide via Increasing MGMT and ANPG in a m(6)A Dependent Manner. Front Oncol. 2021 Jul 15;11:702983. doi: 10.3389/fonc.2021.702983. eCollection 2021.
Ref 2 ClinicalTrials.gov (NCT00003847) VX-710, Doxorubicin, and Vincristine for the Treatment of Patients With Recurrent Small Cell Lung Cancer. U.S. National Institutes of Health.